Contents

1 Extrapolation of Preclinical Data into Clinical Reality – Translational Science
   T. Singer .................................................. 1

2 Smarter Candidate Selection – Utilizing Microdosing in Exploratory Clinical Studies
   P. Buchan .................................................... 7

3 The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
   J. Kuhlmann .................................................. 29

4 Using Exposure – Response and Biomarkers to Streamline Early Drug Development
   J. Venitz ...................................................... 47

5 Experiences with Dose Finding in Patients in Early Drug Development: The Use of Biomarkers in Early Decision Making

6 Genotype and Phenotype Relationship in Drug Metabolism
   I. Roots, G. Laschinski, F. Arjomand-Nahad, J. Kirchheiner, D. Schwarz, J. Brockmöller, I. Cascorbi, T. Gerloff ........... 81
7 Clinical Trials in Elderly Patients
S.H.D. Jackson ........................................... 101

8 Dose Finding in Pediatric Patients
G. Henze .................................................. 111

9 Integration of Pediatric Aspects
into the General Drug Development Process
K. Rose ..................................................... 123

10 Current Stumbling Blocks in Oncology Drug Development
C.D. Gimmi ................................................. 135

11 Exploratory IND: A New Regulatory Strategy
for Early Clinical Drug Development in the United States
N. Sarapa ................................................... 151

12 Ethnic Aspects of Cancer Trials in Asia
T.W.T. Leung ............................................... 165

13 Evaluation of the Effect on Cardiac Repolarization
(QTc Interval) of Oncologic Drugs
J. Morganroth ............................................. 171

14 The Role of PET Scanning
in Determining Pharmacoselective Doses
in Oncology Drug Development
P. Price .................................................... 185

15 Biometrical Aspects of Drug Development
D. Machin, S-B. Tan ..................................... 195

16 Preventing Postmarketing Changes in Recommended Doses
and Marketing Withdrawals
C. Peck .................................................... 209

Previous Volumes Published in This Series ..................... 217
Appropriate Dose Selection - How to Optimize Clinical Drug Development
Venitz, J.; Sittner, W. (Eds.)
2007, XVI, 216 p., Hardcover
ISBN: 978-3-540-27867-2